[{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"Radius Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Benuvia Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"oral solution","sponsorNew":"Benuvia Therapeutics \/ Radius Health","highestDevelopmentStatusID":"8","companyTruncated":"Benuvia Therapeutics \/ Radius Health"},{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"Chromocell Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Diclofenac","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Benuvia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Benuvia Therapeutics \/ Chromocell Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Benuvia Therapeutics \/ Chromocell Corporation"},{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"VA CSRD","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Benuvia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Benuvia Therapeutics \/ VA CSRD","highestDevelopmentStatusID":"12","companyTruncated":"Benuvia Therapeutics \/ VA CSRD"}]

Find Clinical Drug Pipeline Developments & Deals by Benuvia Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : VA will conduct a Drug Clinical Trial with SYNDROS® (dronabinol) oral solution, approved by the FDA to help improve nausea and vomiting caused by anti-cancer medicine (chemotherapy) in adults.

                          Brand Name : Syndros

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 13, 2024

                          Lead Product(s) : Tetrahydrocannabinol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : VA CSRD

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The partnership grants Chromocell access to concentrate on the clinical advancement of a sublingual formulation of a Diclofenac spray designed for treating acute pain.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 27, 2024

                          Lead Product(s) : Diclofenac

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Chromocell Corporation

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Radius Health has acquired the global development and commercialization rights to Benuvia Therapeutics' RAD011, a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases.

                          Brand Name : RAD011

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 06, 2021

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Radius Health

                          Deal Size : $72.5 million

                          Deal Type : Acquisition

                          blank